Antengene Enters into a Global Clinical Collaboration with MSD to Evaluate ATG-022 In Combination with KEYTRUDA May 21, 2025
IDeate-Esophageal01 Ph 3 Trial of Ifinatamab Deruxtecan Initiated in Certain Patients With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma May 21, 2025
EMA approves CTA to conduct pivotal Ph 2B/3 trial of Annamycin + cytarabine in R/R AML patients May 21, 2025
EU approved Neoadjuvant Opdivo + Chemo Followed by Adjuvant Opdivo for Resectable, High-Risk NSCLC with PD-L1 Expression ≥1% based on CheckMate-77T trial results May 21, 2025
FAILED TRIAL: GALAXIES Lung-201 of Belrestotug + Dostarlimab in 1L PD-L1 High NSCLC Patients did not meet PFS endpoint May 21, 2025
U.S. FDA granted Fast Track Designation for ZL-1310 for Treatment of Extensive-Stage SCLC May 21, 2025
FDA Approves EMRELIS (telisotuzumab vedotin-tllv) for Adults With Previously Treated Advanced NSCLC With High c-Met Protein Overexpression May 21, 2025
Tempus Enters Multi-Year Strategic Collaboration With Boehringer Ingelheim to Advance Its Cancer Pipeline May 21, 2025
AbbVie and ADARx Pharmaceuticals to Develop Next-Gen siRNA Therapies Across Multiple Therapeutic Areas May 21, 2025
Atossa Announced Strategic Decision to Pursue Metastatic Breast Cancer Indication for (Z)-endoxifen May 21, 2025
Leap Therapeutics undergoes strategic restructuring to prioritize clinical development of sirexatamab in CRC resulting in an approximately 50% reduction in workforce May 21, 2025
Tempus Enters Multi-Year Strategic Collaboration with Boehringer Ingelheim to Advance its Cancer Pipeline May 21, 2025
Nearly 50 Sites Activated Across U.S. for Pivotal Ph 2 ALPHA3 Trial with Cemacabtagene Ansegedleucel (Cema-Cel) in 1L Consolidation in LBCL May 21, 2025
Successful End of Ph 2 Meeting with US FDA on Ph 3 Registrational Study Design for PT-112 in Patients with Metastatic CRPC Announced May 21, 2025
GTB-3650 Ph 1 Trial Advanced to Cohort 2 Following Successful Initial Human Dosing and Evidence of Early Immune Activation Signals May 21, 2025
